Previous close | 2.6320 |
Open | 1.8560 |
Bid | 0.0000 x 200000 |
Ask | 0.0000 x 200000 |
Day's range | 1.7840 - 1.9700 |
52-week range | 0.9760 - 4.4020 |
Volume | |
Avg. volume | 732 |
Market cap | 125.15M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pe
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 patients (33%) with a confirmed partial response and all 6 patients (100%) with disease control - - Preliminary pharmacokinetic and pharmacodynamic analyses are supportive of PROBODY® T-Cell Engager platform mechanism o
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeuti